Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor
1. 系统已在2025-09-26 09:16:24对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: https://doi.org/10.1021/acs.jmedchem.5c01526
文献链接: https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01526
其他信息:
出版社: American Chemical Society (ACS)
作者: Sam E. Mann; Julien Lefranc; Omar Alkhatib; Roch Boivin; Jörg Bomke; Robert T. Byrne; Carolina P. Cassona; Xiaoling Chen; Irina Cornaciu; Paula Costales; Owen A. Davis; Lizbeth DeSelm; Elias Elinati; Bruce Follows; Alessandro Galbiati; Christoph Göldner; Jasvinder K. Hayre; Catherine Jorand-Lebrun; Claudio A. Lademann; Birgitta Leuthner; Jayesh B. Majithiya; Catarina F. Malta; Bethany Mason; Claire L. McWhirter; Bernd Neff; J. Willem M. Nissink; Ulrich Pehl; Carl Petersson; Andrea Pica; Maria Filipa Pinto; Eeson Rajendra; Christin Rakers; Ana Toste Rêgo; Helen M. R. Robinson; Ada Sala-Hojman; Theresia A. Schaedler; Paul J. L. Schürmann; Diana O. Silva; Graeme C. M. Smith; Fiona Sorrell; Gina R. Webster; Frank T. Zenke; Robert A. Heald; Lars T. Burgdorf
